RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancer

Retrieved on: 2025-02-06 17:22:11

Tags for this article:

Tyrosine kinase receptors

Lung cancer

ROS1

Pyrazoles

Lorlatinib

Non-small-cell lung cancer

RET proto-oncogene

Cancer

Vanderbilt University School of Medicine

Click the tags to see associated articles and topics

RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancer. View article details on hiswai:

Excerpt

This finding highlights how cancers can adapt to treatment and the importance of ongoing genetic testing to guide therapy decisions. NSCLC is the most ...

Article found on: www.news-medical.net

View Original Article